IOBT
IO Biotech·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
Gap Up
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IOBT
Io Biotech, Inc.
A biotechnology company that develops and commercializes immunotherapies for cancer treatment
Ole Maales Vej 3, DK-2200 Copenhagen N, Denmark
--
IO Biotech, Inc., was incorporated in Delaware on May 25, 2021. The company is a clinical-stage biopharmaceutical company developing novel, immune-modulated cancer therapies based on its T-win technology platform. The company's product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. The company believes that this represents a shift in cancer management, and the company's product candidates have the potential to become the cornerstone of a variety of solid tumor treatment options. The company's T-win platform is a new approach to cancer immunotherapy designed to activate naturally occurring T cells to drive targeted immunosuppressive mechanisms.
Company Financials
EPS
IOBT has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.1, missing expectations. The chart below visualizes how IOBT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
